central nervous system
Julius Clinical appoints Bassem Saleh as CEO
October 16, 2025Julius Clinical, cardiometabolic diseases, central nervous system
Julius Clinical, a Netherlands-based clinical research organisation (CRO), has appointed Bassem Saleh as its new chief executive officer (CEO). Saleh …
Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
July 28, 2025Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
Angelini Pharma to acquire Arvelle Therapeutics in $960 million deal
January 6, 2021Research and Development Angelini Pharma, central nervous system
Angelini Pharma is set to acquire Arvelle Therapeutics, a biopharmaceutical company focused on bringing innovative treatments to patients suffering from …
US biotech company to try resurrect the clinically dead
May 4, 2016Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect
A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …
Teva buys majority stake in genomic analysis firm
August 4, 2015Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis
Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …
